Antisense Therapeutics Ltd ATHJF:OTCPK

RT Quote | Exchange | USD
Last | 3:23 PM EST
0.1385quote price arrow down-0.0083 (-5.654%)
Volume
150
52 week range
0.02 - 0.19

...

Loading . . .

KEY STATS

  • Open0.1385
  • Day High0.1385
  • Day Low0.1385
  • Prev Close0.1468
  • 52 Week High0.19
  • 52 Week High Date01/26/21
  • 52 Week Low0.02
  • 52 Week Low Date03/24/20
  • Market Cap72.05M
  • Shares Out488.79M
  • 10 Day Average Volume13,689.63
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change177

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-14.92
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Antisense Therapeutics Ltd News

There is no recent news for this security.

Latest ATHJF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic...
Robert Moses
Non-Executive Chairman
Phillip Hains
Chief Financial Officer
Address
6 Wallace Ave, Toorak
Melbourne, VIC
3142
Australia